Zepbound for Sleep Apnea: What Patients Are Navigating
Tirzepatide is the first medication approved for obstructive sleep apnea. What patients report about the months on CPAP in between, repeat sleep studies, and who gets to graduate.
· By Shashank Bhosale
The press does not currently name a clinical reviewer of record. Read about contributor roles and the review process before using health information. Editors & Contributors.
For years, sleep apnea treatment meant one thing: a machine and a mask. That changed when tirzepatide — the GLP-1 medication sold as Zepbound — became the first drug approved for obstructive sleep apnea in adults with obesity, after trials showed major reductions in breathing interruptions. For the millions who quietly abandoned their CPAP in a closet, the question arrived immediately: is this the way out?
What the approval actually covers
The indication is specific: moderate-to-severe obstructive sleep apnea in adults with obesity, where excess tissue contributes to airway collapse. The medication treats the apnea by treating the weight — which means results build over months, not nights, and people whose apnea has other drivers, including anatomy, may improve less or not at all.
What people navigating it report
Those months in between are the part patients describe most: staying on CPAP while the medication works, repeat sleep studies to measure real change, and the strange suspense of waiting to learn whether their apnea was mostly weight-driven. Some describe graduation — a follow-up study showing mild or resolved apnea, and nights without the mask for the first time in years. Others describe improvement that helps but does not free them, and a recalibrated relationship with a therapy they expected to escape. Sleep physicians' consistent warning threads through the accounts: stopping CPAP on your own, on faith, is where people get hurt.
The honest frame
People who have been through it describe the medication as a second lever, not a replacement — and the sleep study, not the scale, as the referee.
Fifty first-person accounts of CPAP, insomnia, and the pursuit of decent sleep live on our Sleep Disorders shelf; begin with our sleep reading guide.
Companion reading, not medical advice. Never stop apnea treatment without a sleep specialist and follow-up testing.
The Reading Room publishes personal stories and editorial notes from our press. Everything here is companion reading — never medical advice, diagnosis, or treatment. For guidance about your own health, please speak with a qualified clinician. Read how we collect and edit patient testimony in our Editorial Standards, or meet the press at The Masthead.
If this piece was useful, the volumes below hold fifty full-length accounts from people who have been through it — the part an article can only summarise.
